RESUMEN
BACKGROUND: The iodine status of the French population has been improved since 1952. As iodine requirements increase during pregnancy, the World Health Organization recommended in 2005 systematic iodine supplementation for pregnant women. Our work tried to assess the benefits and risks of iodine supplementation during pregnancy. METHODS: We reviewed the international literature from 1991 to 2011 and consulted the main references databases. Keywords were combined with boolean operators AND and OR. Selected studies were assessed with Consort grid. RESULTS: Among 226 papers, 99 were original articles. After analysis, 13 studies were included in this review. A favorable trend toward iodine supplementation from pregnancy desire to the end of pregnancy was observed. Iodine supplementation may prevent psychomotor and neuro-intellectual disorders. CONCLUSION: Iodine status of pregnant women could be improved before pregnancy by more widespread use of iodized salt and iodine-enriched bread in French households. A randomized controlled trial is recommended to confirm the benefit of iodine supplementation.
Asunto(s)
Enfermedades Carenciales/tratamiento farmacológico , Yodo/deficiencia , Yodo/uso terapéutico , Complicaciones del Embarazo/tratamiento farmacológico , Ensayos Clínicos como Asunto/estadística & datos numéricos , Enfermedades Carenciales/epidemiología , Suplementos Dietéticos/efectos adversos , Femenino , Humanos , Estudios Observacionales como Asunto/estadística & datos numéricos , Embarazo , Complicaciones del Embarazo/epidemiología , Medición de Riesgo , Índice de Severidad de la EnfermedadRESUMEN
A better understanding of molecular mechanisms responsible for tumorigenesis has allowed the development of targeted drugs designed to improve the outcome of cancer. In endocrine tumors, several molecules have demonstrated efficacy in terms of progression free survival during phase III trials such as vandetanib and cabozantinib in medullary thyroid carcinoma, sorafenib in differentiated thyroid carcinoma and everolimus or sunitinib for pancreatic neuroendocrine tumors. Rare cancer network has allowed ongoing phase III trials in malignant pheochromocytoma and adrenocortical carcinoma. However, to date no specific predictive biomarker has yet been identified for a personalized cancer medicine. We review recent advances in endocrine oncology concerning molecular targets identification, targeted therapies and predictive or prognostic markers.
Asunto(s)
Neoplasias de las Glándulas Endocrinas/tratamiento farmacológico , Terapia Molecular Dirigida , Antineoplásicos/uso terapéutico , Carcinoma Neuroendocrino , Ensayos Clínicos Fase III como Asunto , Supervivencia sin Enfermedad , Everolimus , Humanos , Indoles/uso terapéutico , Tumores Neuroendocrinos/tratamiento farmacológico , Niacinamida/análogos & derivados , Niacinamida/uso terapéutico , Neoplasias Pancreáticas/tratamiento farmacológico , Compuestos de Fenilurea/uso terapéutico , Piperidinas/uso terapéutico , Pronóstico , Pirroles/uso terapéutico , Quinazolinas/uso terapéutico , Sirolimus/análogos & derivados , Sirolimus/uso terapéutico , Sorafenib , Sunitinib , Neoplasias de la Tiroides/tratamiento farmacológico , Resultado del TratamientoRESUMEN
AIM: To assess clinical features, treatment and outcome of Hypothalamo-pituitary (HP) sarcoidosis and to determine whether HP is associated with a particular clinical phenotype of sarcoidosis. DESIGN: Multicentric retrospective study. METHODS: Retrospective chart review. Each patient was matched with two controls. RESULTS: Twenty-four patients were identified (10 women, 14 men). Their median age at the sarcoidosis diagnosis was 31.5 years (range: 8-69 years). HP involvement occurred in the course of a previously known sarcoidosis in 11 cases (46%), whereas it preceded the diagnosis in 13 patients (54%). All but two patients had anterior pituitary dysfunction, 12 patients presented with diabetes insipidus. The most common hormonal features were gonadotropin deficiency (n=21), TSH deficiency (n=15) and hyperprolactinemia (n=12). Magnetic Resonance Imaging (MRI) revealed infundibulum involvement (n=8), pituitary stalk thickness (n=12) and involvement of the pituitary gland (n=14). All but two patients received prednisone. After a mean follow-up of 4 years, only two patients recovered from hormonal deficiencies. MRI abnormalities improved or disappeared in 12 cases under corticosteroid. There was no correlation between the hormonal dysfunctions and the radiologic outcomes. Patients with HP sarcoidosis had significantly more frequent sinonasal localizations and neurosarcoidosis and required a systemic treatment more frequently than controls. CONCLUSION: Although HP sarcoidosis is unusual, physicians should be aware that such specific localization could be the first manifestation of sarcoidosis. HP involvement is associated with general severity of sarcoidosis. MRI abnormalities can improve or disappear under corticosteroid treatment, but most endocrine defects are irreversible.
Asunto(s)
Enfermedades del Sistema Nervioso Central , Enfermedades Hipotalámicas , Hormonas Hipotalámicas , Sistema Hipotálamo-Hipofisario/efectos de los fármacos , Hormonas Hipofisarias , Sarcoidosis , Adulto , Anciano , Biopsia , Estudios de Casos y Controles , Enfermedades del Sistema Nervioso Central/diagnóstico , Enfermedades del Sistema Nervioso Central/tratamiento farmacológico , Enfermedades del Sistema Nervioso Central/metabolismo , Enfermedades del Sistema Nervioso Central/fisiopatología , Niño , Monitoreo de Drogas , Femenino , Glucocorticoides/administración & dosificación , Humanos , Enfermedades Hipotalámicas/diagnóstico , Enfermedades Hipotalámicas/tratamiento farmacológico , Enfermedades Hipotalámicas/metabolismo , Enfermedades Hipotalámicas/fisiopatología , Hormonas Hipotalámicas/análisis , Hormonas Hipotalámicas/metabolismo , Sistema Hipotálamo-Hipofisario/fisiopatología , Hipotálamo/metabolismo , Hipotálamo/patología , Imagen por Resonancia Magnética/métodos , Masculino , Hipófisis/metabolismo , Hipófisis/patología , Hormonas Hipofisarias/análisis , Hormonas Hipofisarias/metabolismo , Prednisona/administración & dosificación , Sarcoidosis/diagnóstico , Sarcoidosis/tratamiento farmacológico , Sarcoidosis/metabolismo , Sarcoidosis/fisiopatología , Resultado del TratamientoRESUMEN
Brain radiotherapy is a frequent and overlooked cause of pituitary deficiency in adults which may alter patients' health and quality of life. Hormonal consequences have been better studied in children. The onset of hormonal deficiencies depends on the dose delivered to the pituitary-hypothalamic region while their incidence and severity depends on dose fractionating and follow-up duration. Somatotrophic function is the first affected, 90% of patients being GH deficient 10 years after radiotherapy. Other anterior pituitary functions are affected later and less frequently. While initial damage occurs in the hypothalamus, accounting for mild hyperprolactinemia in 30-50% of cases, diabetes insipidus is never observed. Direct pituitary deficiency may occur later. Responses to ACTH or GHRH-arginine tests may be normal for several years though an ACTH and/or GH deficiency has been demonstrated by an insulin tolerance test, which is considered as the gold standard. When the cranio-spinal area--including the neck--has been irradiated, primary thyroid deficiency might occur. Repeated cervical ultrasonographic follow-up is mandatory to exclude radiation-induced thyroid cancer. The gonadotrophic function might be altered after small doses of irradiation causing precocious puberty, while at higher doses delayed puberty or true gonadotrophic deficiencies are more often observed. Combined radio- and chemotherapy might result in mixed central and peripheral deficiencies that might be difficult to diagnose. When radiotherapy is performed in adulthood, GH deficiency is less common, although the sequence of hormonal deficiencies is similar to that observed in children. Prospective longitudinal studies are required to determine the time course and sequence of onset of each deficiency, in order to tailor the monitoring of these patients to their specific needs.
Asunto(s)
Encéfalo/efectos de la radiación , Hipopituitarismo/diagnóstico por imagen , Radioterapia/efectos adversos , Hormona Adrenocorticotrópica/fisiología , Adulto , Salud , Humanos , Hipotálamo/efectos de la radiación , Masculino , Calidad de Vida , CintigrafíaRESUMEN
Severe obesity exposes one to an increased risk of cardiovascular mortality. Gastroplasty has been shown to induce substantial weight loss and to improve the atherogenic profile of severely obese subjects. However, vitamin deficiencies after gastroplasty have been reported. Because hyperhomocysteinemia, an independent risk factor for cardiovascular disease, is influenced by nutritional status (and especially by folate intake), we hypothesized that a marginal folate deficiency induced by gastroplasty could promote hyperhomocysteinemia. Thus, plasma homocysteine concentrations were measured by high-performance liquid chromatography in 53 severely obese patients (body mass index = 42 +/- 1), before and 1 yr after vertical gastroplasty. Plasma homocysteine concentrations increased, on an average, from 9.9 +/- 0.4 to 12.8 +/- 0.6 micromol/L (P < 0.0001). This increase in homocysteine levels was observed in two thirds of the subjects, leading to clear-cut hyperhomocysteinemia (>15 micromol/L) in 32%. The changes in homocysteine concentrations were correlated to weight loss (P < 0.001) and to decrease in plasma folate concentrations (P < 0.01). Whereas gastroplasty induced a mean 32-kg weight loss and a striking improvement in conventional risk factors, the occurrence of iatrogenic hyperhomocysteinemia might hamper the benefit of surgery on cardiovascular risk in most of the patients. Our results further support use of a systematic efficient folate supplementation after gastroplasty.
Asunto(s)
Gastroplastia/efectos adversos , Homocisteína/sangre , Obesidad/sangre , Obesidad/cirugía , Adulto , Glucemia/metabolismo , Enfermedades Cardiovasculares/etiología , Enfermedades Cardiovasculares/prevención & control , HDL-Colesterol/sangre , Femenino , Ácido Fólico/sangre , Humanos , Insulina/sangre , Lipoproteína(a)/sangre , Masculino , Estado Nutricional , Factores de Riesgo , Triglicéridos/sangre , Pérdida de PesoRESUMEN
The protective role of selenium (Se), given as a Se-rich yeast, selenomethionine or selenomethionine + vitamin E supplement, toward changes in lipid, peroxide, and fatty acid distribution in tissues of streptozotocin-induced diabetic rats, was investigated, after 24 wk of disease. Diabetes increased liver thiobarbituric acid-reactive substances and conjugated dienes; Se supplement completely corrected these changes. In kidney, as in heart, the peroxide levels were not significantly changed by diabetes. In diabetic rat liver, a significant drop in triglycerides and phospholipids (P < 0.05) was observed; this was modulated by Se + vitamin E supplementation. Se + vitamin E supplementation also inhibited the decrease in 18:2n-6 and the increase in 22:6n-3 observed in liver of diabetic rats, changes which reflect altered glycemic control. In kidney, heart, and aorta, diabetes produced some changes in lipid content and fatty acid distribution, especially an increase in heart triglycerides which was also corrected by the Se supplement. Se supplementation to diabetic rats also increased 18:0 ether-linked alcohol, 20:4 n-6, and 22:5 n-3 in cardiac lipids. In aorta, Se + vitamin E significantly increased 20:5 n-3. These polyunsaturated fatty acids are precursors, in situ, of prostaglandin I2 (PGI2) and PGI3 which may protect against cardiovascular dysfunction. In kidney, conversely, Se decreased 20:4 n-6, the precursor of thromboxane A2 implicated in diabetic glomerular injury. Thus Se, and more efficiently Se + Vitamin E supplementation, in experimental diabetes could play a role in controlling oxidative status and altered lipid metabolism in liver, thereby maintaining favorable fatty acid distribution in the major tissues affected by diabetic complications.
Asunto(s)
Diabetes Mellitus Experimental/metabolismo , Suplementos Dietéticos , Lípidos/farmacocinética , Peróxidos/farmacocinética , Selenio/farmacología , Vitamina E/farmacología , Animales , Antioxidantes/metabolismo , Aorta/química , Aorta/metabolismo , Riñón/química , Riñón/metabolismo , Hígado/química , Hígado/metabolismo , Masculino , Miocardio/química , Miocardio/metabolismo , Ratas , Ratas Sprague-Dawley , Selenio/administración & dosificación , Distribución Tisular , Vitamina E/administración & dosificaciónRESUMEN
Twenty-nine obese female Zucker rats (fa/fa) were fed with a laboratory chow supplemented or not with a selenium-rich yeast (Selenion), or Selenion + vitamin E, or vitamin E alone. Twelve lean female Zucker rats (Fa/Fa) of the same littermates fed with the same diet were used as control. After 32 wk of diet, obesity induced a large increase in plasma insulin and lipid levels. A significant decrease in the plasma vitamin E/triglycerides ratio (p<0.005) and an increase in plasma thiobarbituric reactive substances (TBARS) (p<0.005) were also observed. Plasma selenium and vitamin E increased in all supplemented rats. The plasma insulin level was decreased by selenion supplementation and the vitamin E/triglycerides ratio was completely corrected by double supplementation with Selenion + vitamin E. TBARS were also efficiently decreased in two obese groups receiving vitamin E. In plasma, adipose tissue and aorta, obesity induced an increase in palmitic acid (C16:0), a very large increase in monounsaturated fatty acids (palmitoleic acid C16:1, stearic acid C18:1) associated with a decrease in polyunsaturated n-6 fatty acids (linoleic acid C18:2 n-6, arachidonic C20:4 n-6). These alterations in fatty acid distribution were only partly modulated by Se and vitamin E supplements. However, in the aorta, antioxidant treatment in obese rats significantly reduced the increase in C16:0 and C16:1 (p<0.05 and p<0.01, respectively) and the decrease in arachidonic acid (p<0.05). These changes could be beneficial in the reduction of insulin resistance and help to protect the vascular endothelium.
Asunto(s)
Tejido Adiposo/efectos de los fármacos , Aorta/efectos de los fármacos , Lípidos/análisis , Selenio/farmacología , Vitamina E/farmacología , Tejido Adiposo/química , Animales , Antioxidantes/farmacología , Aorta/química , Glucemia/análisis , Peso Corporal/efectos de los fármacos , Colesterol/sangre , Suplementos Dietéticos , Ácidos Grasos/análisis , Ácidos Grasos/sangre , Ácidos Grasos/química , Femenino , Resistencia a la Insulina , Lípidos/sangre , Obesidad/metabolismo , Ratas , Ratas Zucker , Selenio/sangre , Sustancias Reactivas al Ácido Tiobarbitúrico/análisis , Vitamina E/sangreRESUMEN
In vitro 30 min of incubation with selenomethionine (Sm) + vitamin E multiplied by about five platelet selenium (Se) decreased significantly platelet thrombin and ADP-induced aggregation decrease. Four groups of streptozotocin-induced diabetic rats were fed with a supplemented purified diet with an Se-rich yeast (Selenion): DSel, Sm: DSm, Sm alpha-tocopherol: DSmE or unsupplemented diet: D. After 24 wk of supplementation, only a decrease in thrombin-induced aggregation in group DSel compared to DSm and DSmE and D was observed. However, after 24 wk of diet compared to 14 wk, in group D and DSm, a significant increase in thrombin-induced aggregation occurred (p < 0.0001), whereas a significant decrease in groups DSel and DSmE (p < 0.0001, p < 0.03) was noted. After 21 wk of diet, in DSmE, platelet adhesion to fibronectin was significantly decreased compared to group D (p < 0.05). These changes in DSmE were associated with a significant decrease in platelet sorbitol (p < 0.02) and a very significant increase in platelet Se (p < 0.0005). Sm associated with vitamin E would appear more efficient to prevent oxidative damage of diabetic platelet membrane and thus to modulate its hyperactivity.
Asunto(s)
Plaquetas/efectos de los fármacos , Diabetes Mellitus Experimental/sangre , Ácidos Grasos/sangre , Selenometionina/farmacología , Sorbitol/sangre , Vitamina E/farmacología , Adenosina Difosfato/farmacología , Animales , Plaquetas/química , Plaquetas/fisiología , Cromatografía Líquida de Alta Presión , Diabetes Mellitus Experimental/tratamiento farmacológico , Diabetes Mellitus Experimental/fisiopatología , Modelos Animales de Enfermedad , Sinergismo Farmacológico , Alimentos Fortificados , Modelos Lineales , Masculino , Agregación Plaquetaria/efectos de los fármacos , Inhibidores de Agregación Plaquetaria/farmacología , Inhibidores de Agregación Plaquetaria/uso terapéutico , Ratas , Ratas Sprague-Dawley , Selenio/sangre , Selenometionina/administración & dosificación , Selenometionina/uso terapéutico , Trombina/farmacología , Vitamina E/metabolismo , Vitamina E/uso terapéuticoRESUMEN
Seventy rats were separated into five groups: one group of 12 was used as a control and received a purified diet, and four groups of streptozotocin-induced diabetic rats, totalling 58, were fed the same diet without or with selenium (Se) supplementation. Of the noncontrol rats, 14 were without supplementation (Group D), 14 were fed a Se-rich yeast diet (i.e., selenion) (Group DSel), 14 received selenomethionine (Group DSm), and 16 received selenomethionine + tocopherol acetate (Group DSmE). Supplementation with Se in all groups was 0.99 micromole/100g of diet and with tocopherol acetate was 0.145 micromole/100 g. All diabetic rats were mildly balanced by insulin. After 24 weeks of diet, plasma glucose tended to decrease in diabetic Se-supplemented groups DSmE > DSm > DSel versus Group D. In DSm and DSmE groups, plasma lipid peroxides also decreased compared with Group D, but this decrease reached significance only for DSmE (P < 0.01 for both TBARS and conjugated dienes). Plasma triglycerides also decreased in DSm and DSmE groups versus Group D (P < 0.01; P < 0.05, respectively). At the same time, Se increased significantly in kidneys of Groups DSel and DSm versus D and more weakly in Group DSmE, but in this case was associated with a large increase of vitamin E. These beneficial effects of selenium supplement and more so of selenium combined with vitamin E were associated with a protection of kidneys in diabetic rats which found expression in a significant correction of renal hyperfiltration (P < 0.05) and in a diminution of the number and severity of glomerular lesions (P < 0.0005).
Asunto(s)
Diabetes Mellitus Experimental/complicaciones , Nefropatías Diabéticas/prevención & control , Alimentos Fortificados , Selenio/uso terapéutico , Vitamina E/uso terapéutico , Animales , Glucemia/efectos de los fármacos , Diabetes Mellitus Experimental/sangre , Diabetes Mellitus Experimental/patología , Nefropatías Diabéticas/patología , Glomérulos Renales/patología , Masculino , Tamaño de los Órganos , Ratas , Ratas Sprague-Dawley , EstreptozocinaRESUMEN
The aim of the present study was to investigate the functional and/or pathological significance of the hemispherical lateralization of TRH using radioimmunoassay to determine the TRH concentration of nuclei and areas within the hypothalamus of suicide patients, with matching measurement being carried out on control subjects. In suicide patients, we found no significant difference in TRH concentration between the left and right intrahypothalamic structures, while the group used as control subjects (see Borson-Chazot, 1986) showed a significant left side predominance in the ventromedial nucleus, paraventricular nucleus and area dorsalis. As regards the TRH concentration in the right intrahypothalamic structures, no significant difference was found between the suicide patients and the control subjects. The absence of the left TRH predominance for the three intra-hypothalamic structures in question may be of pathological significance.
Asunto(s)
Hipotálamo/metabolismo , Suicidio , Hormona Liberadora de Tirotropina/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Lateralidad Funcional , Humanos , Hipotálamo/anatomía & histología , Masculino , Persona de Mediana Edad , RadioinmunoensayoRESUMEN
We previously observed that under a 12-hour light/12-hour dark schedule (lights off at 19.00 h), adult male Sprague-Dawley rats showed a circadian rhythm for serum thyroid-stimulating hormone (TSH) with a zenith near midday. In the present work, the ontogenesis of serum TSH rhythm was determined as well as pituitary TSH variations. In addition, hypothalamic and blood TRH were measured in these rats aged 15, 25, 40 and 70 days when sacrificed. As from the first age studied (15 days), a hypothalamic thyrotropin-releasing hormone (TRH) circadian rhythm was present. The mesor and the amplitude of this hypothalamic TRH rhythm increased while the rats were growing up, in contrast with the decrease observed for these parameters as far as blood TRH circadian rhythm is concerned. The time of the acrophase moved from 17.32 h in the 15-day-old rats to 13.57 h in the 70-day-old rats, being constantly in phase opposition with the blood TRH acrophase. The low amplitude pituitary TSH circadian rhythm detected in the young rat disappeared in the adult while, in contrast, the serum TSH rhythm became consistent to reach the well-characterized circadian midday peak in the 70-day-old rats.
Asunto(s)
Ritmo Circadiano , Ratas Endogámicas/crecimiento & desarrollo , Hormona Liberadora de Tirotropina/metabolismo , Tirotropina/metabolismo , Envejecimiento , Animales , Hipotálamo/metabolismo , Masculino , Adenohipófisis/metabolismo , Ratas , Tirotropina/sangre , Hormona Liberadora de Tirotropina/sangreRESUMEN
Thyrotropin-releasing hormone (TRH) and luteinizing hormone-releasing hormone (LH-RH) have been measured by radioimmunoassay in individual human hypothalamic nuclei. A significant lateralization has been found for TRH in the ventromedial, dorsal and paraventricular nuclei, with higher concentration in the left side. In contrast LH-RH values did not differ between the left and the right side. This finding represents an additional example of cerebral specialization and the first report of lateralized peptide distribution in the human hypothalamus.
Asunto(s)
Hormona Liberadora de Gonadotropina/análisis , Hipotálamo/análisis , Hormona Liberadora de Tirotropina/análisis , Adulto , Anciano , Anciano de 80 o más Años , Autopsia , Humanos , Hipotálamo/patología , Persona de Mediana Edad , Distribución TisularRESUMEN
Thyrotropin-releasing hormone (TRH) or thyroid-stimulating hormone (TSH) was measured by radioimmunoassay in the incubation medium of rat hypothalami or anterior pituitary halves, respectively. We studied the effect of opioid peptide addition (10(-8) to 10(-6) M) on TRH or TSH release. alpha- or beta-Endorphin decreased TRH release in a dose-dependent manner while only 10(-6) M Leu- or Met-enkephalin decreased TRH release. These inhibitory effects were prevented by addition of naloxone (10(-5) M). In the dose range used none of the opioid peptides modified TSH release. These results indicate that opioid peptides may play a role in the regulation of thyrotropin secretion via a hypothalamic action on TRH release.